KEYMAKER-U04 substudy 04B: First-line (1L) enfortumab vedotin (EV) plus pembrolizumab (pembro)-based immune checkpoint inhibitor (ICI) combinations for advanced urothelial cancer (UC).
No Thumbnail Available
Authors
Van Der Heijden M.S.
Sarfaty M.
Caglevic C.
GrossGoupil M.
Rosenbaum E.
Lee J.L.
Powles T.
Sridhar S.S.
Rojas C.
Shin S.J.
Contact
Check for full-text access
Issue Date
2026
Type
Article
Language
Keywords
Alternative Title
Abstract
EV + pembro is the preferred standard 1L therapy for patients with locally advanced or metastatic UC (la/mUC). The randomized, open-label phase 1/2 substudy 04B in the KEYMAKER-U04 umbrella study (NCT05845814) aimed to build on the efficacy of this combination and evaluated EV + pembro-containing ICI coformulations and EV + pembro as 1L treatment in participants (pts) with la/mUC. Method(s): Adult pts without prior systemic therapy for la/mUC and an ECOG PS of 0-1 were randomized 1:1:1 to EV + coformulated favezelimab (fave; anti-LAG3)/pembro 800 mg/200 mg (arm A), EV + coformulated vibostolimab (vibo; anti-TIGIT)/pembro 200 mg/200 mg (arm B), and EV + pembro 200 mg (arm C). Pts received EV 1.25 mg/kg IV on d1 and d8 Q3W until disease progression, intolerable toxicity, or study withdrawal, and pembro or pembro-containing coformulations IV on d1 Q3W for <=2 years. A safety lead-in was performed for the first 10 pts in each of EV + fave/pembro and EV + vibo/pembro arms per modified toxicity probability interval with dose-limiting toxicity (DLT) monitoring in cycle 1. Primary end points: ORR per RECIST v1.1 by blinded independent central review (BICR) and safety. Secondary end points: PFS and DOR per RECIST v1.1 by BICR. Result(s): 124 pts received treatment (arm A: n = 41; arm B: n = 41; arm C: n = 42). Median follow-up (time from randomization to data cutoff [Dec 16, 2024]) (range) was 11.9 mo (9.7-17.0), 11.7 mo (9.7-16.3), and 11.8 mo (9.8-16.8), respectively. Most pts were male (74%); median age was 69 yrs. DLT was reported for 1/10 pts on EV + fave/pembro and no pts on EV + vibo/pembro. Efficacy results are in the table. Any-grade TRAEs were similar across all arms (arm A: 100%; arm B: 100%; arm C: 97.6%); grade >=3 TRAEs were reported for 56.1%, 73.2%, and 61.9% of pts, respectively. Immune-mediated AEs and infusion reactions were reported for 65.9% pts in arm A, 53.7% in arm B, and 42.9% in arm C; immune-mediated AEs with > 10% higher incidence in any EV + pembro-containing ICI coformulation were hypothyroidism (31.7%, 14.6%, and 2.4%, respectively), severe skin reactions (24.4%, 29.3%, and 14.3%, respectively), hyperthyroidism (22.0%, 4.9%, and 4.8%, respectively), and infusion reactions (17.1%, 2.4%, and 0%, respectively). Conclusion(s): In pts with la/mUC, the addition of LAG3- or TIGIT-targeted ICIs to EV + pembro did not have a clinically significant impact on efficacy. No new safety signals were identified. Incidence of certain immune-mediated AEs was higher with pembro-containing coformulations compared to EV + pembro. Clinical trial information: NCT05845814. [Table presented] Copyright © 2026 by American Society of Clinical Oncology
Description
Citation
Publisher
License
Journal
Journal of Clinical Oncology
Volume
44